Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1998-1-21
|
| pubmed:abstractText |
Some chronic renal failure patients respond poorly to recombinant human erythropoietin (rHuEPO). In continuous ambulatory peritoneal dialysis (CAPD) patients, such a poor response may indicate inadequate dialysis or low body iron stores. To correct iron deficiency, once-a-week intravenous iron supplementation is recommended. However, hemodialysis patients receive iron supplements three times a week. This study was designed to compare the efficacy of iron supplementation between once-weekly and twice-weekly regimens. In both groups, rHuEPO doses were similar. Seventeen CAPD patients were studied. All had hemoglobin levels less than 10 g/dL. Ten patients were given 100 mg intravenous iron once weekly, and 7 were given 50 mg intravenous iron twice weekly until a total iron dose of 600 mg was achieved (stage I). The patients were crossed over to receive another 600 mg iron (stage II). Hematocrit increased significantly in patients receiving twice-a-week iron supplementation (+3.8% and 6%) compared to those receiving once-a-week iron supplementation (+1.3% and 1.4%) during stages I and II. The ferritin levels were not different between the groups. In conclusion, rHuEPO is more effective when administered with intravenous iron.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin,
http://linkedlifedata.com/resource/pubmed/chemical/Ferric Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Ferritins,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Sucrose,
http://linkedlifedata.com/resource/pubmed/chemical/Transferrin,
http://linkedlifedata.com/resource/pubmed/chemical/iron(III)-hydroxide sucrose complex
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1197-8554
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
109-12
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9360661-Adult,
pubmed-meshheading:9360661-Anemia,
pubmed-meshheading:9360661-Drug Administration Schedule,
pubmed-meshheading:9360661-Drug Therapy, Combination,
pubmed-meshheading:9360661-Erythropoietin,
pubmed-meshheading:9360661-Female,
pubmed-meshheading:9360661-Ferric Compounds,
pubmed-meshheading:9360661-Ferritins,
pubmed-meshheading:9360661-Hematocrit,
pubmed-meshheading:9360661-Humans,
pubmed-meshheading:9360661-Injections, Intravenous,
pubmed-meshheading:9360661-Kidney Failure, Chronic,
pubmed-meshheading:9360661-Male,
pubmed-meshheading:9360661-Middle Aged,
pubmed-meshheading:9360661-Organization and Administration,
pubmed-meshheading:9360661-Peritoneal Dialysis, Continuous Ambulatory,
pubmed-meshheading:9360661-Recombinant Proteins,
pubmed-meshheading:9360661-Sucrose,
pubmed-meshheading:9360661-Transferrin
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
The efficiency of fractionated parenteral iron treatment in CAPD patients.
|
| pubmed:affiliation |
Department of Internal Medicine, Medical School of Ege University, Izmir, Turkey.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|